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a b s t r a c t
Compounds in cocoa and chocolate have established cardiovascular beneﬁts, including beneﬁcial effects
on insulin resistance, a risk factor for type 2 diabetes mellitus. The aims of this study was to investigate
relations between habitual chocolate intakes and diabetes mellitus. Cross-sectional and prospective
analyses were undertaken on 953 community-dwelling participants (mean age 62 years, 59% women)
from the Maine-Syracuse Longitudinal Study (MSLS). Habitual chocolate intakes, measured using a food
frequency questionnaire, were related to prevalence of diabetes mellitus (cross-sectionally) and with risk
of diabetes measured approximately ﬁve years later (prospectively). We also examined the relation
between diabetes (the predictor) and chocolate consumption (the outcome) up to 30 years later.
Chocolate intake was inversely associated with type 2 diabetes. Compared to participants who consumed
chocolate more than once per week, those who never or rarely ate chocolate exhibited a signiﬁcantly
higher odds of having type 2 diabetes 5 years later (OR: 1.91, 95% CI: 1.03, 3.55, p ¼ 0.04), after
adjustment for cardiovascular, lifestyle and dietary factors including other polyphenol-rich beverages.
However, individuals diagnosed with diabetes prior to the nutritional assessment consumed lower
amounts of chocolate at the time of the dietary assessment. Our ﬁndings suggest that relations between
chocolate and type 2 diabetes may be bi-directional.
© 2016 Elsevier Ltd. All rights reserved.
1. Introduction
Chocolate is a widely consumed food throughout the world, with
particularly high intakes in the United States (Statista). With a rich
natural complexity, it is commonly associated with pleasure and
enjoyment, as well as having a wide-ranging number of medicinal
beneﬁts (Macht & Mueller, 2007; Wilson, 2010). More recent scien-
tiﬁc interest has been directed at the cardiovascular beneﬁts derived
from chocolate and cocoa consumption (Grassi, Desideri, & Ferri,
2010; Heiss, Keen, & Kelm, 2010; Hooper et al., 2012). Flavonoids,
naturally occurring polyphenolic compounds present in plant-based
foods, represent up to 20% of the compounds present in cocoa beans
(Sokolov, Pavlova, Klosterhalfen, & Enck, 2013), and may be respon-
sible for the beneﬁts to cardiovascular function (Grassi et al., 2010).
Interest in the biological and clinical effects of cocoa ﬂavanols
and cocoa-based products such as chocolate is increasing (Grassi
et al., 2015; Hooper et al., 2012). To date, there here have been
two large epidemiological analyses of the association between
long-term chocolate intake and diabetes (Greenberg, 2015; Oba
et al., 2010). In the United States, Greenberg (Greenberg, 2015)
found an inverse association between frequency of chocolate con-
sumption and diabetes risk over a 13-year follow-up in the pro-
spective Atherosclerosis Risk in Communities Cohort (ARIC). A large
analysis of over 13,000 Japanese individuals (Oba et al., 2010)
showed a signiﬁcant inverse association between the consumption
of chocolate snacks and risk of diabetes among men, over a 10-year
period. This research is supported by a number of short-term trials
demonstrating that ingestion of dark chocolate (Grassi, Lippi,
Necozione, Desideri, & Ferri, 2008, 2005) and cocoa ﬂavanols
(Davison, Coates, Buckley, & Howe, 2008) can improve insulin
sensitivity, while a longer term trial has demonstrated that con-
sumption of ﬂavonoid rich chocolate for one year can reduce pe-
ripheral insulin resistance in women with type 2 diabetes (Curtis
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et al., 2012).
It may be hypothesised that diabetics however, avoid or limit
their intake of high-sugar foods and sugar-sweetened beverages as
a result of their diagnosis. Few, if any studies have asked if the as-
sociation between chocolate intake and diabetes occurs because
knowledgeable and treated diabetics limit their chocolate intake.
Longitudinal prospective data are necessary to answer this
question.
Using data collected from participants in the Maine-Syracuse
Longitudinal Study (MSLS), residents of Central New York, USA,
the aim of the present study was to determine 1) whether habitual
chocolate intakes were associated with diabetes mellitus, with
control for cardiovascular, lifestyle and dietary factors; and 2)
whether pre-existing diabetes was related to chocolate intake
assessed up to 30 years later.
2. Materials and methods
2.1. Participants
The MSLS was a study of cardiovascular risk factors and cogni-
tive functioning in community living adults (Elias et al., 2009;
Robbins, Elias, Elias, & Budge, 2005). The MSLS consists of ﬁve co-
horts deﬁned by time of entry into the study (1975e2000). The
MSLS employs a time-lagged-longitudinal-cohort design with new
subjects featuring an initial wave of data collection and then new
subjects recruited into the study every ﬁve years with the same
recruitment procedures as employed for every wave.
At initial recruitment, participants were living independently in
Syracuse, New York or in the adjacent Central New York area. The
only exclusions at recruitment were diagnosis of or treatment for
psychiatric illness, alcoholism and inability to comprehend English.
The present study utilized data from participants at waves 1 to 5
(1975e2000), 6 (2001e2006) and 7 (2006e2010). Dietary data
were collected for the ﬁrst time at wave 6. At wave 6, participants
were excluded for the following reasons: missing data on nutri-
tional or health variables (n ¼ 58), history of acute stroke (n ¼ 28),
probable dementia (n ¼ 8), undertaking renal dialysis treatment
(n ¼ 5), inability to read English (n¼ 1), prior alcohol abuse (n¼ 1),
and not participating in the diabetes outcome study (n ¼ 16),
leaving a sample of 956 study participants. Of these 956 partici-
pants with dietary data at wave 6, 953 individuals also had diabetes
data at waves 1 to 5. This allowed for a prospective design in which
diabetes status at waves 1 to 5 was used to predict chocolate intake
at wave 6, as well as a cross-sectional examination of the relation
between chocolate consumption and diabetes status at wave 6. Of
those who participated at wave 6, the mean time period of
participation leading up to wave 6 was 11.3 ± 7.7 years.
Eight-hundred twenty-two subjects who provided cross-
sectional data on chocolate and diabetes (outcome) at wave 6
were invited back to the laboratory for testing at wave 7. Six-
hundred nine participants completed data collection. Nineteen
participants had incomplete data at wave 7 and were excluded
leaving a sample of 590. This allowed for prospective analyses in
which chocolate intakes at wave 6 were used to predict diabetes at
wave 7. Mean time between waves 6 and 7 was 4.7 ± 0.6 years. The
MSLS study design is shown in Fig. 1.
Stroke, deﬁned as a focal neurological deﬁcit of acute onset
persisting more than 24 h, was based on self-report and was
conﬁrmed by a record review indicating a diagnosis of acute stroke.
Clinical diagnoses of dementia were determined from cognitive
data and medical records using the National Institute of Neuro-
logical and Communicative Diseases and Stroke/Alzheimer's Dis-
ease and Related Disorders Association (NINCDS-ADRDA) criteria
(McKhann et al., 1984) and conﬁrmed using the ICD-10 Guidelines
(World Health Organization, 1992).
This study was conducted according to the guidelines estab-
lished by the Declaration of Helsinki and all procedures were
approved by the University of Maine Institutional Review Board.
Written informed consent was obtained from all subjects.
2.2. Procedure and assessment
2.2.1. Dietary intake
Dietary intake was assessed using the Nutrition and Health
Questionnaire, (Kaaks & Riboli, 1997; Riboli & Kaaks, 1997), in
which participants were required to stipulate how frequently they
consume foods including meat, ﬁsh, eggs, breads, cereals, rice and
pasta, fruit, vegetables, dairy foods, chocolate, nuts, other snack-
type foods, and beverages including alcohol. Participants were
required to stipulate how frequently they currently consume each
food, from six response options: never, seldom, once/week, 2e4
times/week, 5e6 times/week, and once or more per day. The di-
etary data was therefore a reﬂection of nutritional habits at the
time of data collection (i.e. at wave 6).
The median score within each response option was used to es-
timate total intakes per week of the major food groups and total
energy; for example, 2e4 times per week was estimated at 3. The
mean number of times each food was consumed on a daily basis
was calculated for all foods in the questionnaire. As portion sizes
were not stipulated to participants, these totals are an estimate of
the number of times each food was consumed. Foods were cat-
egorised into one of ﬁve major food groups - grains, fruits, vege-
tables, protein foods, and dairy foods - based on the USDA Food
Guide Pyramid (United States Department of Agriculture, 2011).
Chocolate intakewas categorised into three intake groups: <1 serve
per week, 1 serve per week, and >1 serve per week. Chocolate was
not differentiated according to type, i.e. dark, milk, or white
chocolate.
2.2.2. Diabetes assessment
Standard assay methods were employed (Elias et al., 2006) to
obtain fasting plasma glucose (mg/dL), in addition to total choles-
terol (TC, mg/dL), low-density lipoprotein cholesterol (LDL, mg/dL),
high-density lipoprotein cholesterol (HDL, mg/dL), triglycerides
(mg/dL) and C-reactive protein (CRP, mg/L), following an overnight
fast. Diabetes mellitus was deﬁned as fasting glucose level of
126 mg/dL, being treated with anti-diabetic medication following
a medical diagnosis of diabetes.
2.2.3. Demographics and physical health assessment
Demographic, socioeconomic and lifestyle characteristics were
obtained from the Nutrition and Health Questionnaire (Kaaks &
Riboli, 1997; Riboli & Kaaks, 1997). Data obtained included smok-
ing history, marital status andmedical history. Physical activity was
measured with the Nurses' Health Study Activity Questionnaire, a
validated measure of time spent engaging in various physical ac-
tivities (Wolf et al., 1994). Education level was obtained through
self-report and ranged from 4 to 20 years.
Body weight was measured with participants wearing light
clothing to the nearest 0.1 kg, and height was measured with a
vertical ruler to the nearest 0.1 cm. Body mass index (BMI) was
calculated as weight in kilograms divided by height in metres
squared. Waist circumference (in centimetres) was taken over light
clothing, using a non-extendable measuring tape, at the level of the
iliac crest. Obesity was deﬁned as BMI 30 kg/m2, and cardiovas-
cular disease (CVD) was based upon self-reported history of coro-
nary artery disease, myocardial infarction, congestive heart failure,
transient ischemic attack, or angina pectoris, conﬁrmed by medical
records. Automated blood pressure (BP) measures (GE DINAMAP
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100DPC-120XEN, GE Healthcare) were taken in the right arm ﬁve
times each in recumbent, standing and sitting position after a su-
pine rest for 15 min, and the 15 values were averaged for systolic
and diastolic BP. Hypertension was deﬁned as BP of 140/
90 mmHg, or on medication.
2.3. Statistical analyses
Participant demographics, health and dietary variables at wave
6 were compared according to diabetes status (Y/N) at waves 1 to 5
(Table 1) and diabetic status at wave 6. Independent samples t-tests
were used for continuous variables and Chi-square for categorical
variables for the comparative analyses of demographic, health and
dietary variables. Normality of distribution for all health and di-
etary variables was ascertained by visual inspection of the histo-
grams describing the distribution of scores.
For the cross-sectional and prospective analyses, logistic
regression (categorical regression analyses) was used to relate
chocolate intakes with the likelihood of having diabetes mellitus.
Diabetes status was compared across three chocolate intake cate-
gories:<1 serve per week,1 serve per week, and >1 serve per week.
The highest chocolate intake group served as the reference group.
Three covariate models were used to adjust for confounding; these
variables were selected based upon correlational analyses (related
signiﬁcantly to chocolate intake and diabetes) or theoretical justi-
ﬁcation. Other polyphenol-rich foods and beverages (such as tea,
coffee, red wine, fruit) were included in the ﬁnal model if they
correlated with either the predictor (chocolate intake) or outcome
(diabetes status at wave 6). The following models were employed
for all analyses:
Model 1: Basic: age (years) þ gender þ education
(years) þ ethnicity;
Extended 1: Basic þ total cholesterol (mg/dL), obesity (Y/N),
hypertension (Y/N), C-reactive protein (CRP; mg/L);
Extended 2: adjusted for Basic, Extended 1 þ physical activity
(MET-hours/day), total grains (serves/day), coffee (cups/day), red
wine (glasses/week).
In our ﬁnal step, we used general linear modelling to assess
whether pre-exiting diabetes (at waves 1e5) predicted chocolate
intake between 5 and 30 years later (wave 6).
Except for sensitivity analyses the same covariates were taken
from the examination in which chocolate consumption was
assessed, wave 6. All statistical analyses were performed with
PASW forWindows® version 21.0 software (formerly SPSS Statistics
Inc. Chicago, IL, USA); P < 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Participant characteristics and chocolate consumption
Table 1 shows the demographic, health-related variables, and
dietary intakes forMSLS participants (N¼ 953) at wave 6, according
to diabetes status at waves 1 to 5 (Y/N). Those with diabetes had
signiﬁcantly higher BMI, glucose levels, systolic blood pressure and
CRP, but lower total cholesterol than those without diabetes. A
signiﬁcantly higher proportion of diabetics were obese, had CVD
and hypertension, compared with non-diabetics. Diabetics
consumed more grains and diet soft drinks, but less chocolate,
sweets and alcohol than non-diabetics. A comparison of diabetics
and non-diabetics at wave 6 showed the same differences in terms
of health characteristics and dietary habits.
3.2. Chocolate consumption and diabetes in the MSLS: cross-
sectional and prospective
Chocolate intake was inversely associated with type 2 diabetes
(Table 2). Cross-sectionally, the prevalence of type 2 diabetes was
over twice as high in those who consumed chocolate less than once
per week compared to those who ate chocolate more than once per
week (OR: 2.15, 95% CI: 1.27, 3.67, p ¼ 0.005; extended 2 model),
with full adjustment for cardiovascular risk factors, obesity, phys-
ical activity and other dietary factors, including redwine and coffee.
Prospectively, individuals who consumed chocolate never or
rarely had nearly double the risk of having type 2 diabetes
approximately 5 years later (OR: 1.91, 95% CI: 1.03, 3.55, p ¼ 0.040),
compared to those who ate chocolate more than once per week
(with full statistical adjustment).
Waves 1-5: 1975-2000 
Diabetes assessment at each wave 
Wave 7: 2006-2010 
Diabetes assessment 
Wave 6: 2001-2006 
Diabetes assessment 
Dietary assessment 
N=953 (subset): Prospective analyses relating diabetes 
status at waves 1-5 with chocolate intake at wave 6
N=590 (subset): Prospective analyses relating chocolate 
intake at wave 6 with diabetes status at wave 7 
Total N=956: Cross-sectional analyses relating diabetes 
status at wave 6 and chocolate intake at wave 6  
Fig. 1. Flow diagram of the MSLS study design. Sample sizes at waves 1e5 and 7 are subsets of the total sample at these waves and represent the number of participants with
available data at wave 6 also.
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3.3. Chocolate consumption and incident diabetes
The odds ratios associated with incident diabetes (new cases at
wave 7 compared to wave 6) were not signiﬁcantly different as a
function of level of chocolate consumption (all p values > 0.05).
Mean chocolate intakes were slightly lower amongst those who did
develop diabetes (n¼ 30; mean chocolate intake¼ 1.7 ± 1.9 serves/
week) compared to those who did not develop diabetes (n ¼ 498;
mean chocolate intake ¼ 2.0 ± 1.8 serves/week) in this 5-year time
period (p ¼ 0.4). Of those individuals who did develop diabetes
between waves 6 and 7, 30% consumed chocolate more than once
per week; whilst 41% of individuals who did not go on to develop
diabetes consumed chocolate more than once per week.
3.4. Pre-existing diabetes and chocolate consumption: prospective
Nearly 5% of participants at waves 1 to 5 had type 2 diabetes. As
shown in Table 3, those with diabetes at these earlier waves ate
signiﬁcantly less chocolate at wave 6 than those without diabetes.
Statistically adjusting for demographic, health and dietary factors,
including physical activity and intakes of coffee and red wine, those
without diabetes ate chocolate approximately twice per week;
compared to amean intake of 1.2 serves per week by diabetics (fully
extended model, p ¼ 0.009). The same signiﬁcant difference in
meanwave 6 chocolate intakes were observed whenwe eliminated
diabetics at waves 1 to 4, and performed the analyses comparing
non-diabetics with persons who were diagnosed as diabetic at
wave 5 (approximately 5 years between waves, data not shown).
3.5. Test of interactions and sensitivity analyses
Tests for interactions (multiplicative effects) with age, sex, and
BMI were done. In each case the main effect of the risk factor was
included in the model with the interaction term and the basic
model was employed. Interaction tests were not statistically sig-
niﬁcant (p > 0.05). Replacing obesity (Y/N) with BMI (kg/m2) and
waist circumference in all models did not alter the results, and
neither did replacing total cholesterol with HDL- and LDL-
Table 1
Demographic, health and nutritional factors at wave 6, according to diabetes status at waves 1e5, in the MSLS sample (N ¼ 953).
Variable (at wave 6) Diabetesa status (at waves 1e5)
No (n ¼ 908, 95.3%) Yes (n ¼ 45, 4.6%) p-value*
Mean SD Mean SD
Age, years 62.1 12.7 66.0 10.7 0.042
Education, years 14.8 2.7 13.3 2.3 <0.001
Smoking, cigarettes/day 1.3 5.3 0.3 2.2 0.2
Body mass index, kg/m2 29.1 5.6 32.8 9.2 <0.001
Physical activity, MET-hrs/week 21.0 28.0 13.0 18.8 0.06
Total cholesterol, mg/dL 203 39.6 179 32.4 <0.001
HDL cholesterol, mg/dL 53.9 15.5 46.6 11.8 0.002
LDL cholesterol, mg/dL 122 33.3 103 29.5 <0.001
Systolic blood pressure, mm Hg 130 21.5 140 23.8 0.004
Diastolic blood pressure, mm Hg 70.4 10.1 69.8 9.1 0.7
Fasting blood glucose, mg/dL 96.6 23.5 147 59.0 <0.001
Triglycerides, mg/dL 143 114 148 76.9 0.8
(median 115) (median 127)
C-reactive protein, mg/L 0.41 0.47 0.61 0.62 0.006
(median 0.25) (median 0.34)
Dietary variables
Chocolate intake, times/week 2.0 1.8 1.2 1.5 0.009
Total grains, serves/day 3.7 2.0 4.4 2.4 0.036
Total meats, serves/day 2.0 0.9 2.3 0.9 0.1
Total fruit, serves/day 1.6 1.0 1.7 1.0 0.5
Total vegetables, serves/day 2.8 1.1 2.5 1.0 0.1
Total dairy foods, serves/day 2.0 1.1 2.1 1.1 0.5
Total sweets, serves/day 2.5 2.2 1.6 1.4 0.004
Regular soft drinks, glasses/day 0.4 1.1 0.3 0.5 0.5
Diet soft drinks, glasses/day 0.5 1.2 1.2 1.9 <0.001
Alcohol, g/week 37.8 71.3 11.8 29.7 0.015
Total intake, total serves/day all food groups 14.8 4.6 14.6 4.5 0.8
n % n % p-values*
Gender 0.2
Males 367 40.4 23 51.1
Females 541 59.6 22 48.9
Ethnicity 0.037
African American 52 5.7 6 13.3
Other 856 94.3 39 86.7
Obesityc at wave 6 322 37.2 25 56.8 0.009
CVDb at wave 6 123 13.5 15 33.3 <0.001
Hypertensiond 550 60.6 39 86.7 <0.001
Abbreviations: CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metabolic equivalent.
*P-values were obtained by analysis of variance for continuous variables or the chi-square test for categorical variables.
a Diabetes mellitus deﬁned as fasting glucose level of 126 mg/dL, or being treated with anti-diabetic medication.
b CVD based upon self-reported history of coronary artery disease, myocardial infarction, congestive heart failure, transient ischemic attack, or angina pectoris, conﬁrmed by
medical records.
c Obesity deﬁned as BMI 30 kg/m2.
d Hypertension deﬁned as BP  140/90 mmHg or being treated with anti-hypertensive medication.
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cholesterol. Replacing hypertension with systolic and diastolic BP
(mmHg) in the statistical models did not alter the results. The main
cross-sectional and prospective results remained unchanged when
participants with CVD at wave 6 were excluded.
4. Discussion
The present study suggests an inverse association between
chocolate consumption and diabetes. The ﬁndings indicate that
those who consume moderate amounts of chocolate are at lower
risk for diabetes mellitus. This was seen in the cross-sectional
analysis conducted at wave 6, and prospectively between waves 6
and 7, following full adjustment for other polyphenol-rich bever-
ages including coffee and red wine.
Two large epidemiological studies support the notion that
consuming a moderate amount of chocolate may reduce the risk of
diabetes (Greenberg, 2015; Oba et al., 2010). Data from 7802 ARIC
participants showed that compared to individuals who ate 1 oz.
(28 g) of chocolate less than once per month, those who ate it at
least monthly had signiﬁcantly reduced risk of being diagnosed
with diabetes over 10 years (Greenberg, 2015). The greatest risk
reduction of 34% was observed for those who consumed chocolate
2 to 6 times per week. Consuming chocolate more than once per
day did not lower the risk further. This is consistent with the
viewpoint that the added fat and calories in chocolate beyond a
moderate intake may override the positive effects of the cocoa
ﬂavanols in chocolate. As for our study, the type of chocolate
consumed (dark/milk/white) was not speciﬁed.
In a large Japanese study, Oba et al (Oba et al., 2010). examined
the risk of diabetes in relation to the consumption of a number of
high-caffeine foods and beverages, including coffee, tea and choc-
olate. A 35% reduced risk for diabetes was observed in men who
consumed chocolate at least once per week, compared to those
who ate chocolate never or almost never. Similar associations were
implied inwomen. These two studies, suggest that the greatest risk
reduction may be observed amongst moderate chocolate con-
sumers (at least once per week).
Supporting these studies, two thorough, recent reviews of the
literature (Grassi et al., 2015; Hooper et al., 2012) suggest that cocoa
and chocolate may offer cardiometabolic protection. The positive
effects of chocolate are attributed to the cocoa ﬂavanols. Epidemi-
ological and clinical studies have repeatedly shown that high-
ﬂavonoid foods can improve endothelial function, as assessed by
ﬂow mediated dilatation, by elevating NO bioavailability and
bioactivity (Grassi et al., 2009, 2010, 2013). Conditions of insulin
resistance, such as diabetic states, are usually linked to endothelial
dysfunction and decreased NO bioavailability. Our ﬁndings
remained with the addition of coffee and red wine, which both
contain polyphenols (Carluccio et al., 2003; Hecimovic, Belscak-
Cvitanovic, Horzic, & Komes, 2011).
Larger, longer-term clinical trials to conﬁrm the possible car-
diovascular beneﬁts derived from cocoa and chocolate consump-
tion have been recommended (Grassi et al., 2015; Hooper et al.,
2012). For example, it is unknown whether the high energy,
sugar, and fat content of chocolate may weaken or nullify the
beneﬁts of cocoa. More attention needs to be paid to the ﬂavanol
concentration, sugar and calorie content of cocoa-based foods such
as chocolate (Grassi et al., 2015).
Our ﬁndings when we related wave 1e5 diabetes status to
chocolate consumption at wave 6 do raise the possibility that re-
lationships between chocolate and diabetes may, in part, reﬂect a
practice in which diabetics choose to eat less chocolate for health
reasons. Those who were diabetic at waves 1 to 5 consumed less
chocolate at wave 6. The chocolate-diabetes relation may be bi-
directional. This may be likened to inactivity foreshadowing
obesity but obesity being associated with poorer lifestyle habits
such as lower levels of physical activity, smoking and drinkingmore
alcohol (Crichton et al., 2014; Goday et al., 2016). At wave 6, the
diabetic individuals consumed fewer sweets, less alcohol and more
diet soft drinks and grains than non-diabetics; these practices are
consistent with limiting chocolate consumption. These practices
are also consistent with nutritional recommendations made for
diabetics during this period of time (1975e2000). Until only
recently, sugar was ‘forbidden’ for diabetics, with recommenda-
tions based on tradition rather than evidence (Wheeler, 2000).
Diabetes nutrition recommendations have cycled between greater
and lesser amounts of different foods, food groups, and
Table 3
Multivariate-adjusted mean and standard error for chocolate intake (times per
week) at wave 6, according to diabetes status (N ¼ 953) at waves 1-5.
Diabetes status, waves 1-5
Model No (n ¼ 908, 95.3%) Yes (n ¼ 45, 4.6%) pa
Mean 95% CI Mean 95% CI
Basicb 2.00 1.85, 2.07 1.34 0.80, 1.87 0.029
Extended 1 1.97 1.85, 2.10 1.42 0.86, 1.97 0.05
Extended 2 1.98 1.84, 2.11 1.15 0.55, 1.75 0.009
Values are mean and 95% conﬁdence interval (CI) for chocolate intake (times per
week).
a p for difference between means.
b Basic: adjusted for age, education, sex, ethnicity; Extended 1: adjusted for
Basic þ total cholesterol (mg/dL), obesity (Y/N), hypertension (Y/N), CRP (mg/L);
Extended 2: adjusted for Basic, Extended 1 þ physical activity (MET-hours/day),
total grains (serves/day), coffee (cups/day), red wine (glasses/week).
Table 2
Odds of having diabetes at waves 6 (cross-sectional) and 7 (prospective), according to chocolate intake at wave 6 in the MSLS.
Modela Chocolate intake group Diabetesb wave 6 (N ¼ 956) Diabetesb wave 7 (N ¼ 560)
OR 95% CI p OR 95% CI p
Basic <1 serve/week 1.92 1.15, 3.20 0.012 2.08 1.20, 3.61 0.010
1 serve/week 1.39 0.80, 2.44 0.2 1.18 0.63, 2.22 0.6
>1 serve/week 1.00 1.00
Extended 1 <1 serve/week 2.01 1.17, 3.47 0.012 1.98 1.10, 3.57 0.023
1 serve/week 1.25 0.68, 2.33 0.5 1.16 0.60, 2.27 0.7
>1 serve/week 1.00 1.00
Extended 2 <1 serve/week 2.15 1.27, 3.67 0.005 1.91 1.03, 3.55 0.040
1 serve/week 1.23 0.67, 2.29 0.5 1.27 0.64, 2.52 0.5
>1 serve/week 1.00 1.00
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
a Basic: adjusted for age, education, sex, ethnicity; Extended 1: adjusted for Basic þ total cholesterol (mg/dL), obesity (Y/N), hypertension (Y/N), CRP (mg/L); Extended 2:
adjusted for Basic, Extended 1 þ physical activity (MET-hours/day), total grains (serves/day), coffee (cups/day), red wine (glasses/week).
b Diabetes: 126 mg/dL or on anti-diabetic medication.
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macronutrients throughout the history of diabetes nutrition ther-
apy, ranging from starvation treatment in 1915 to evidence-based
recommendations made in 2002 (Franz, 2004; Franz et al., 2002,
2003). The most commonly held food belief was that diabetics
should avoid added sugars and sweets, and restrict naturally
occurring sugars, based on the assumption that sucrose and other
sugars would aggravate hyperglycaemia as they are more rapidly
digested and absorbed, and cause a greater increase in blood sugar
levels than starches (Franz et al., 2003). During the period of time in
which waves 1 to 5 were conducted, this was the prevalent belief.
Clinical trials have subsequently demonstrated that it is the total
amount of carbohydrate consumed that is more important than the
source or type, (Franz et al., 2002). Nutrition goals for diabetes are
therefore similar to those all individuals should strive for to achieve
a balanced and healthy diet, with consideration given to total
caloric intake in relation to energy needs (American Diabetes
Association, 2008). Our investigation of the literature indicates a
number of studies that have not taken this dietary modiﬁcation
possibility into consideration, and in our view, it cannot be ruled
out in the absence of clinical trials.
Several limitations of the present study must be acknowledged.
Dietary data were only obtained at wave 6, so we are unable to
examine any change in chocolate intakes over time in relation to
diabetes status at waves 1e5. Chocolate intake was self-reported,
and therefore subject to inherent reporting error. The dietary
questionnaire used did not require the respondent to differentiate
between dark, milk or white chocolate. Most clinical trials have
used dark chocolate as the source of cocoa ﬂavanols. In 2012, the
distribution share of chocolate in the United States by favourite
chocolate type was 57% milk chocolate, 35% dark chocolate, and 8%
white chocolate (Statista). We can therefore make the assumption
that the majority of chocolate consumed in this sample was dark or
milk, both containing cocoa ﬂavanols to varying degrees. It is
certainly plausible that the ﬁndings are driven by those consuming
milk or dark chocolate only. We are unable to calculate the actual
quantities of chocolate and cocoa associated with diabetes status,
due to the nature of the questionnaire. Finally, covariates were used
fromwave 6, as not all health variables, such as CVD, were collected
at earlier waves, and oral glucose tolerance testing was not per-
formed at any waves of the MSLS.
We were able to statistically control for a number of cardio-
vascular, lifestyle and dietary variables that may confound the as-
sociation between habitual chocolate consumption and health
outcomes such as diabetes. We were able to examine cross-
sectional and prospective relations between diet and health.
Importantly, we were able to consider whether persons with dia-
betes consumed less chocolate 4e30 years later. Moreover there is
evidence that theymodiﬁed aspects of their diet in away consistent
with reduction of intake of sweets as one would expect of diabetic
individuals during the time period represented at waves 1e5
(1975e2000).
5. Conclusions
Clinical trials are necessary to further explore relations between
diabetes and chocolate, with consideration given to type, nutri-
tional content and quantity. Relations may reﬂect both self-
selection away from chocolate and the adverse inﬂuence of low
chocolate levels on prevalent diabetes. Amoderate chocolate intake
of several times per week may be related to the reduction of the
incidence (new cases) of diabetes mellitus, but it is also possible
that those diagnosed with diabetes limit or avoid chocolate. Further
studies are necessary to examine the inﬂuence of chocolate con-
sumption on diabetes mellitus and behavior around food choices.
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